In February 2026 , the company announced positive results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its injectable GLP-1 receptor agonist
Cannot redeclare control with same name "grid_3_cta_background_color"
Yes, Klinic accepts hundreds of insurance plans, including Medicare and Medicaid, for both prescriptions and consultations
Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
The Zepbound vial is a single-dose option for self-pay patients without insurance coverage, shipped directly to their door
They show that when you make preventative care accessible and effective, people will embrace it